These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35053526)

  • 1. Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers.
    Turchiano A; Loconte DC; De Nola R; Arezzo F; Chiarello G; Pantaleo A; Iacoviello M; Bagnulo R; De Luisi A; Perrelli S; Martino S; Ranieri C; Garganese A; Stella A; Forleo C; Loizzi V; Marinaccio M; Cicinelli E; Cormio G; Resta N
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.
    Lebedeva A; Veselovsky E; Kavun A; Belova E; Grigoreva T; Orlov P; Subbotovskaya A; Shipunov M; Mashkov O; Bilalov F; Shatalov P; Kaprin A; Shegai P; Diuzhev Z; Migiaev O; Vytnova N; Mileyko V; Ivanov M
    World J Oncol; 2024 Aug; 15(4):562-578. PubMed ID: 38993246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic landscape of homologous recombination repair and practical outcomes of PARPi therapy in ovarian cancer management.
    Chen M; Lei N; Guo R; Han L; Zhao Q; Zhao Y; Qiu L; Wu F; Jiang S; Tong N; Wang K; Li S; Chang L
    Ther Adv Med Oncol; 2024; 16():17588359241271845. PubMed ID: 39246808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.
    Hirasawa A; Imoto I; Naruto T; Akahane T; Yamagami W; Nomura H; Masuda K; Susumu N; Tsuda H; Aoki D
    Oncotarget; 2017 Dec; 8(68):112258-112267. PubMed ID: 29348823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Testing for Somatic and Germline
    Peixoto A; Pinto P; Guerra J; Pinheiro M; Santos C; Pinto C; Santos R; Escudeiro C; Bartosch C; Canário R; Barbosa A; Gouveia A; Petiz A; Abreu MH; Sousa S; Pereira D; Silva J; Teixeira MR
    Front Oncol; 2020; 10():1318. PubMed ID: 32850417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics.
    Yao Q; Liu Y; Zhang L; Dong L; Bao L; Bai Q; Cui Q; Xu J; Li M; Liu J; Chuai S; Ying J; Zhang Z; Zhou X
    Front Oncol; 2022; 12():709645. PubMed ID: 35186721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer.
    Song Y; Ran W; Jia H; Yao Q; Li G; Chen Y; Wang X; Xiao Y; Sun M; Lu X; Xing X
    Heliyon; 2024 Jan; 10(2):e23684. PubMed ID: 38298632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond
    Germani A; Petrucci S; De Marchis L; Libi F; Savio C; Amanti C; Bonifacino A; Campanella B; Capalbo C; Lombardi A; Maggi S; Mattei M; Osti MF; Pellegrini P; Speranza A; Stanzani G; Vitale V; Pizzuti A; Torrisi MR; Piane M
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32957588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
    Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and outcomes of germline pathogenic variants of homologous recombination repair genes in ovarian cancer.
    Miwa M; Kitagawa M; Asami Y; Kobayashi-Kato M; Watanabe T; Ogasawara A; Hiranuma K; Kato H; Saito M; Miyagi Y; Kato T; Yoshida H; Momozawa Y; Kohno T; Shiraishi K; Hasegawa K
    Cancer Sci; 2024 Oct; ():. PubMed ID: 39385713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector.
    van der Merwe NC; Ntaita KS; Stofberg H; Combrink HM; Oosthuizen J; Kotze MJ
    Front Oncol; 2022; 12():938561. PubMed ID: 36568162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions.
    Guglielmi C; Scarpitta R; Gambino G; Conti E; Bellè F; Tancredi M; Cervelli T; Falaschi E; Cosini C; Aretini P; Congregati C; Marino M; Patruno M; Pilato B; Spina F; Balestrino L; Tenedini E; Carnevali I; Cortesi L; Tagliafico E; Tibiletti MG; Tommasi S; Ghilli M; Vivanet C; Galli A; Caligo MA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinto C; Santos C; Pinheiro M; Escudeiro C; Bartosch C; Silva J; Teixeira MR
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33008098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.